Corvus Pharmaceuticals, Inc.
CRVS Nasdaq
SEC CIK 1626971
Follow Corvus Pharmaceuticals
Weekly email: filings, results
Net income
−$20.3M
−100.3% vs same quarter last year
EPS, diluted
−$0.22
−83.3% vs same quarter last year
Operating cash flow
−$12.2M
−27.7% vs same quarter last year
Operating income
−$21.4M
−102.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$15.3M |
| FY24 | −$62.3M |
| FY23 | −$27M |
| FY22 | −$41.3M |
| FY21 | −$43.2M |
| FY20 | −$6M |
| FY19 | −$46.7M |
| FY18 | −$46.9M |
| FY17 | −$55.7M |
| FY16 | −$36.4M |
| FY15 | −$31.3M |
| FY14 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$33M |
| FY24 | - |
| FY23 | −$24M |
| FY22 | −$27.3M |
| FY21 | −$36.7M |
| FY20 | −$34.9M |
| FY19 | −$37.3M |
| FY18 | −$41.3M |
| FY17 | −$46.5M |
| FY16 | −$30.1M |
| FY15 | −$13.1M |
| FY14 | - |